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Background: Several retinal ischemic diseases can cause neovascular glaucoma (NVG). Trabeculectomy with
mitomycin C (MMC) is a relatively better treatment modality in the management of eyes with NVG than other
glaucoma surgeries. The aim of this study was to investigate the factors that may influence the outcome of
trabeculectomy with MMC for NVG.
Methods: Forty-nine NVG eyes from 43 patients (26 males and 17 females) underwent primary trabeculectomy
with MMC. The mean follow-up period was 16.8 ± 8.1 months (range, 6 to 34 months). Twenty-one eyes of 21
patients received intravitreal bevacizumab (IVB) 3.6 ± 1.8 days before trabeculectomy with MMC. A Kaplan-Meier
survival-curve analysis was used to summarize the cumulative probability of success. We examined the relationship
between the surgical outcome and the following surgical factors: gender, age, history of panretinal photocoagulation,
history of cataract surgery, history of vitrectomy, preoperative IVB, NVG in the fellow eye, and postoperative
complications (hyphema, choroidal detachment, and formation of fibrin) by multivariate analysis.
Results: The survival rate was 83.7% after 6 months, 70.9% after 12 months, and 60.8% after 24 months. The Kaplan-Meier
survival curves showed no significant difference in the survival rate between the eyes with preoperative IVB (n = 21)
and the eyes without preoperative IVB (n = 28) (p = 0.14). The multiple logistic regression analysis showed that
postoperative hyphema (odds ratio, 6.54; 95% confidence interval, 1.41 to 35.97) was significantly associated with the
surgical outcome (p = 0.02).
Conclusions: Postoperative hyphema was significantly correlated with the outcome of trabeculectomy for NVG. There
was no significant association between preoperative IVB and postoperative hyphema or the results of trabeculectomy.
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Several retinal ischemic diseases can cause neovascular
glaucoma (NVG): proliferative diabetic retinopathy (PDR),
central retinal vein occlusion (CRVO), branch retinal vein
occlusion (BRVO), central retinal artery occlusion (CRAO),
and ocular ischemic syndrome (OIS) [1]. Patients with
NVG generally present with elevated intraocular pressure
(IOP), hyphema, and vitreous hemorrhage. If the elevation
in IOP is severe the patient may experience severe pain,
and the elevated IOP often results in disastrous visual loss.* Correspondence: yosida@med.kyushu-u.ac.jp
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unless otherwise stated.NVG is a severe form of glaucoma characterized by
neovascularization and the proliferation of fibrovascular
tissue in the anterior chamber angle. In the early open-
angle glaucoma stage, anti-glaucoma drugs or panretinal
photocoagulation (PRP) may be effective. However, as
the disease progresses, the proliferative fibrovascular
membrane causes angle closure. This stage is not revers-
ible by PRP and is often refractory to anti-glaucoma drugs.
Trabeculectomy with mitomycin C (MMC) is a good
treatment modality in the management of eyes with NVG
[2-4], but its success rate is still poor [5].
The pathogenesis of NVG is related to the production
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zation in the anterior chamber angle [1,6]. Bevacizumab is
a human monoclonal antibody that binds VEGF and
blocks its action. Intravitreal bevacizumab (IVB) was re-
ported to decrease the concentration of VEGF in the
aqueous humor [7], the neovascularization of the anterior
chamber, and the IOP to acceptable levels in NVG pa-
tients [8-12]. Fluorescein angiography and histochemical
investigations demonstrated that there was less vascular
permeability and inflammatory reaction in trabecular tis-
sue with IVB than without IVB [13,14]. Another histo-
pathological investigation indicated that IVB may induce
changes in immature, newly formed vessels, leading to
endothelial apoptosis with vascular regression and indu-
cing the normalization of premature vessels in PDR or
NVG eyes [15]. Therefore, IVB before trabeculectomy sur-
gery is expected to have potential as a surgical adjuvant to
reduce operative bleeding complications.
According to previous reports, patient factors such as
previous PRP [16] and history of preoperative IVB
[16,17] were indicated as good prognostic factors for the
surgical outcome of trabeculectomy for NVG, whereas a
history of vitrectomy [3,18], and younger age [18] were
indicated as adverse prognostic factors. However, it is
not yet known which factors are definite prognostic fac-
tors [3,18]. In addition, to the best of our knowledge
there has been no report about the effect of early post-
operative hyphema on the success rate of trabeculect-
omy with NVG. In the present study, we investigated
the surgical prognostic factors of trabeculectomy.Methods
Patients
We retrospectively reviewed the medical records of 49
NVG eyes from 43 patients (26 males and 17 females)
with the presence of neovascularization in the anterior
chamber angle and uncontrolled IOP. All patients
underwent primary trabeculectomy with MMC at Kyushu
University Hospital, Japan, between January 2008 and
July 2010 and could be followed up for more than
6 months. This study was approved by the Ethics Com-
mittee of Kyushu University (Ethics Approval Number:
19002). No patients underwent any other glaucoma sur-
gery before the primary trabeculectomy. The etiology of
NVG was PDR (43 eyes), CRVO (2 eyes), and CRAO,
BRVO, OIS and uveitis (1 eye each). PRP was performed
as much as possible except for patients who could not
undergo PRP because of vitreous hemorrhage or cor-
neal edema. Excluding those with a history of ischemic
cardiac disease or brain infarction and in poor general
status, 21 eyes of 21 patients received IVB (1.25 mg/
0.05 mL) at 1 to 7 (3.6 ± 1.8) days before trabeculectomy
with MMC after 2009 March.Surgical technique
All 43 patients underwent trabeculectomy with MMC. A
fornix-based conjunctival flap was made. After hemostasis
of the episcleral blood vessels with wet-fluid cautery, a 3 ×
3-mm, half-thickness triangle scleral flap was made. Surgi-
cal sponges soaked in MMC (0.4 mg/mL) were placed
under the conjunctival flap for 3 min, followed by irriga-
tion with 300 mL of physiologic saline. A deep trabecular
block was removed and a peripheral iridectomy was per-
formed. The scleral flap was sutured with 10-0 nylon su-
tures. All patients received topical treatment including
0.5% levofloxacin and 0.1% betamethasone for 1 to
3 months after the operation, and the patients whose IOP
was elevated received anti-glaucoma drugs. Postopera-
tively, argon laser suture lysis was performed, depending
on the level of IOP and the condition of the conjunctival
bleb formation.Data analysis
The criteria for successful surgery were: IOP < 20 mmHg
with or without anti-glaucoma drugs, visual acuity more
than light perception, and no additional glaucoma surgery
(shunt insertion or cyclophotocoagulation). The following
patient data were collected: age, gender, preoperative and
postoperative (1 week, 1, 2, 3, and 6 months after the sur-
gery, and last visit) IOP, lens status, previous surgical ocu-
lar history (except for glaucoma surgery), preoperative and
postoperative visual acuity, the number of preoperative
and postoperative anti-glaucoma drugs the patient had
been taking, and postoperative complications.
Hyphema, one of the potential postoperative compli-
cations of trabeculectomy, was defined as hemorrhage in
the anterior chamber to the extent of making niveau,
even if only a little. Eyes that showed only suspended
red blood cells in the anterior chamber, without making
niveau, were not defined as having hyphema. The pa-
tients’ visual acuity was measured by assessing their
decimal visual acuity, and it was calculated after conver-
sion to the logarithm of the minimum of resolution
(logMAR).
A Kaplan-Meier survival curve was used to estimate the
probability of the success rate. We examined the relation-
ships between the surgical risk factors and the surgical
outcome. We considered the following ten possible risk
factors for surgical outcome: gender, age, history of previ-
ous PRP, history of cataract surgery, history of vitrectomy,
concurrent vitrectomy, preoperative IVB, NVG in the fel-
low eye, postoperative hyphema, postoperative choroidal
detachment, and postoperative formation of fibrin. All var-
iables were treated as categorical variables. Each categor-
ical variable was coded as either 1 or 0 depending on the
presence or absence of the factor, respectively. Frequencies
were compared by chi-square test.
Table 1 Baseline characteristics of 43 patients (49 eyes)






Mean ± SD 55.6 ± 11.5
Range 30–79
Follow-up (months)
Mean ± SD 16.8 ± 8.1
Range 6–34
Preoperative IOP (mmHg)







20-gauge system 28 (57.1%)








Preoperative (mean ± SD) 2.4 ± 0.9








Table 2 Postoperative complications
Disease Eyes (%) Eyes
IVB not IVB
Hyphema 11 (22.4%) 6 5
Formation of fibrin 4 (8.2%) 0 4
Choroidal detachment 5 (10.2%) 1 4
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95% confidence interval (CI) of the following three po-
tential risk factors by using a logistic regression analysis:
history of vitrectomy [3,18], preoperative IVB [16,17],
both of which have been reported to affect the surgical
outcome, and postoperative hyphema. The JMP version
9 statistical package program (Cary, NC) was used to
perform the statistical analyses. A two-sided p-value of
less than 0.05 was considered significant.
Results
Table 1 shows the baseline characteristics of all 49 eyes.
The mean age of the patients was 55.6 ± 11.5 years with
a range from 30 to 79 years. Twelve patients (14 eyes)
were less than 50 years old, and 31 patients (35 eyes)
were ≥ 50 years old. The mean follow-up period was
16.8 ± 8.1 months with a range from 6 to 34 months. All
eyes were followed up for 6 months or more; 34 eyes
were followed for 12 months or more, and 12 eyes were
followed for 24 months or more. The mean preoperative
IOP was 30.4 ± 13.1 mmHg, and the mean last-visit IOP
was 16.0 ± 9.9 mmHg. Forty-two eyes received PRP. The
other 7 eyes could not undergo sufficient retinal photo-
coagulation because of vitreous hemorrhage or corneal
edema. Twenty-one eyes underwent preoperative IVB at
3.6 ± 1.8 (range 1–7) days before trabeculectomy.
Table 2 shows the postoperative complications of tra-
beculectomy with MMC in patients with NVG. Eleven
eyes developed hyphema: 9 eyes at postoperative 1 day,
1 eye at postoperative 2 days, and 1 eye at postoperative
4 days. Four eyes had developed a formation of fibrin in
the anterior chamber, and 5 eyes had developed chor-
oidal detachment as postoperative surgical complica-
tions. Of all 49 eyes, 35 eyes were successes, and 14 eyes
were failures.
Figure 1 is the Kaplan-Meier survival curve of all eyes.
All 49 eyes were evaluated after 6 months, 34 eyes were
evaluated after 12 months, and 12 eyes were evaluated
after 24 months. The survival rate was 83.7% after
6 months, 70.9% after 12 months, and 60.8% after
24 months. Figure 2 is the Kaplan-Meier survival curve
for the two groups (IVB group vs. not-IVB group). Until
23 months after the trabeculectomy, the survival rate of
the IVB group was higher than that of the not-IVB
group, but there was no significant difference between
the two groups (p = 0.41).
Figure 3 is the Kaplan-Meier survival curve of the sur-
gical outcomes of the trabeculectomies with MMC in
eyes with and without hyphema. The survival rate of the
group without hyphema was significantly higher than
the group with hyphema (p < 0.01). Table 3 shows the
frequencies of the surgical risk factors that potentially
influence the results of trabeculectomy for NVG. The
















Figure 1 Kaplan-Meier survival curve of all eyes. The survival rate
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Figure 3 Kaplan-Meier survival curve for the groups with
hyphema vs. without hyphema. Kaplan-Meier survival curve of the
surgical outcomes of trabeculectomies with MMC in eyes with
hyphema (n = 11, continuous line) and eyes without hyphema
(n = 38, dotted line). There was a significant difference between the
two groups (p < 0.01).
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Table 4 shows the results of the multivariate analysis for
the factors that influenced the surgical outcome. In the
multivariate analysis, postoperative hyphema was signifi-
cantly associated with the surgical outcome (p < 0.02).
Discussion
Even with some therapies, the IOP is often increased to
an uncontrolled level, sometimes leading to blindness.
According to a systematic review and meta-analysis of
comparative studies of two or more surgical techniques
(one of which had to be trabeculectomy), including pa-
tients with open-angle glaucoma, trabeculectomy still
offers the possibility of obtaining excellent IOP control
at the long-term follow-up in patients with open-angle
glaucoma [19], whereas the success rate of trabeculect-
omy for NVG is still poor [5]. In the present study, the















Figure 2 Kaplan-Meier survival curve for IVB group vs. not-IVB
group. Kaplan-Meier survival curve of the surgical outcomes of
trabeculectomies with MMC in eyes with IVB (n = 21, continuous
line) and eyes without IVB (n = 28, dotted line). There was no
significant difference between the two groups (p = 0.41).6 months, 70.9% after 12 months, and 60.8% after
24 months.
Several previous studies investigated the success rate
of trabeculectomy with MMC for NVG. One study re-
ported that the cumulative probability of the success of
trabeculectomy was 67.0% after 1 year and 61.8% after 2
to 3 years [3]. According to another report, the probabil-
ity of success at 120, 240 and 360 days after combined
preoperative IVB and trabeculectomy was 87.5%, 79.2%,
and 65.2%, respectively, but the corresponding values
after only trabeculectomy without IVB were 75.0%,
71.9%, and 65.3%, respectively [20]. Our surgical out-
comes in the present study are similar to these reports.
Although there was a trend for less failure in the IVB
group until postoperative 23 months, preoperative IVB
finally did not significantly improve the outcome of
trabeculectomy with MMC for NVG in our study.
Moreover, it did not decrease the risk of postoperative
hyphema. Sugimoto et al. [21], using resected irises from
NVG patients during trabeculectomy, reported that IVB
reduced the neovascularization on the iris surface but
could not completely eliminate neovascularization in the
iris stroma. They also reported that IVB did not prevent
postoperative complications at 1 day after trabeculect-
omy, including hyphema [21]. Takihara et al., performing
IVB 1 to 5 days before the trabeculectomy for NVG pa-
tients, reported that preoperative IVB did not signifi-
cantly improve the surgical outcomes, in common with
our study [20].
In contrast, Saito et al. reported that preoperative IVB
decreased postoperative hyphema and increased the sur-
gical success rate [17]. The discrepancy between these
studies may be due to the different intervals between the
IVB and the trabeculectomy: in the Sugimoto study and
Table 3 Frequencies of surgical risk factors that influence the result of trabeculectomy with MMC for NVG
Variable: Success group (35 eyes) Number of eyes
(Percentage of eyes)




Gender (Male) 20 9 0.65
(57.1%) (64.3%)
Age (50<) 9 5 0.49
(25.7%) (35.7%)
History of previous PRP 30 12 1.00
(85.7%) (85.7%)
History of cataract surgery 29 10 0.37
(82.9%) (71.4%)
History of vitrectomy 23 7 0.31
(65.7%) (50.0%)
Concurrent vitrectomy 18 7 0.93
(51.4%) (50.0%)
Preoperative IVB 16 5 0.52
(45.7%) (35.7%)
NVG in the fellow eye 9 4 0.84
(25.7%) (28.6%)
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1 to 5 days before the trabeculectomy, respectively,
whereas in the Saito study, the IVB was performed 10 ±
11 days before the trabeculectomy. In our study, the IVB
was performed 3.6 ± 1.8 days before the trabeculectomy,
and the results are consistent with the Sugimoto study
and Takihara study. Considering these data, using a suf-
ficiently long interval between the IVB and trabeculect-
omy may be more effective by calming down the activity
of neovascularization in the anterior segment.
Another study demonstrated that NVG eyes with a
history of vitrectomy had poor surgical outcomes after
trabeculectomy [22]. Vitrectomy exacerbates retinal is-
chemia and increases the concentration of inflammatory
cytokines and/or VEGF in the anterior chamber [3]. OurTable 4 Multivariate analysis of the factors that influence
the result of trabeculectomy with MMC for NVG
Variable Odds ratio 95% CI p-value
History of vitrectomy 0.26 0.05–1.21 0.09
Preoperative IVB 0.28 0.05–1.30 0.10
Postoperative hyphema 6.54 1.41–35.97 0.02
CI, confidence interval.present analysis did not find that previous vitrectomy is a
prognostic factor. Thirty eyes had already undergone a vi-
trectomy before trabeculectomy, and 25 eyes underwent a
vitrectomy concurrently to receive more photocoagulation
to the extreme periphery of the retina intraoperatively.
Additional photocoagulation may improve retinal ische-
mia; here it may have led to the satisfactory surgical out-
comes. Moreover, some reports indicated that younger
NVG patients have a poor success rate following trabecu-
lectomy [18], but in the present study we found no signifi-
cant difference in the surgical outcome between patients
under 50 years old (14 eyes) and those ≥ 50 years old
(35 eyes). This may be because there were many more pa-
tients over 50 years old in our study.
Trabeculectomy in NVG patients usually results in fre-
quent postoperative complications and poor surgical out-
comes. Hyphema has been described as the most frequent
postoperative complication of trabeculectomy in NVG pa-
tients [16]. However, there is no report that postoperative
hyphema significantly influences the surgical outcome of
trabeculectomy with NVG. In the present study, hyphema
was the most common postoperative complication, and we
also found that postoperative hyphema was a significant
prognostic factor in trabeculectomy for NVG. Moreover,
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significantly higher serum levels of cytokines such as inter-
leukin (IL)-6, tumor necrosis factor-alpha (TNF-α and
VEGF compared to non-PDR patients [23]. The serum
levels of TNF-α, IL-6, and C-reactive protein (CRP) were
also higher in subjects with arteriosclerotic peripheral vas-
cular disease compared to healthy controls [24].
TNF and IL-1 were reported to be capable of stimulat-
ing the proliferation of Tenon’s capsule fibroblasts [25].
Moreover, Cvenkel et al. indicated that lower levels of
TNF-α and IL-6 in the aqueous humor were associated
with better surgical outcomes in patients undergoing
trabeculectomy [26]. Tripathi et al. reported the results
of an intracameral injection of tissue plasminogen acti-
vator in the anterior chamber for eyes with fibrin clots
and elevated IOP after glaucoma filtering procedures
[27]; soon after the injection, the fibrin clots dissolved
completely and the elevated IOP values decreased to the
normal level. Tripathi et al. suggested that fibrin clots
after filtering surgery provide a scaffold for the forma-
tion of scar tissue in the anterior chamber and in the fis-
tulization tract.
In view of these reports, when hyphema occurs after tra-
beculectomy, increased concentrations of some cytokines
may lead to a failure of conjunctival bleb formation. Add-
itionally, blood flow into the trabecular meshwork may
lead to a stronger wound-healing response or clog the flow
of aqueous humor, but further study is required to test this
notion.
There are a few reports about reducing the incidence of
hyphema following trabeculectomy. Wilson et al. reported
that during trabeculectomy, filling the anterior chamber
with sodium hyaluronate reduced the incidence of postop-
erative hyphema for glaucoma patients with primary
open-angle glaucoma, chronic angle closure glaucoma, con-
genital glaucoma, or NVG [28]; they suggested that the re-
duced incidence was due to a microvascular clotting effect
or the tamponade of higher intraocular pressure. To avoid
unfavorable hyphema, Elgin et al. used direct cauterization
of the iris before iridectomy, and they reported that this
protocol effectively reduced the rate of intraoperative
bleeding and postoperative hyphema in trabeculectomy
for NVG [29]. The direct cauterization of the iris seeking
to reduce postoperative bleeding may be a beneficial new
procedure for better prognosis in NVG patients.
In addition, as a new glaucoma surgery, the Ex-PRESS
drainage device was introduced in 2011 as an alternative to
trabeculectomy [30]. During this operation, iridectomy is
not required, and thus hyphema is less likely compared to
the use of trabeculectomy. The results of our present retro-
spective study indicate that postoperative hyphema could
be a surgical risk factor for failure of trabeculectomy in
NVG, but in light of the study’s retrospective nature, fur-
ther prospective randomized investigations are required.Filling the anterior chamber with ophthalmic viscosurgical
devices intraoperatively, the direct cauterization of the iris,
or the use of the Ex-PRESS drainage device may provide
better prognoses in NVG patients.
Conclusions
In the present study, we found that postoperative hyphema
was a significant prognostic factor in trabeculectomy
for NVG. There was no clear association between pre-
operative IVB and postoperative hyphema or the result
of trabeculectomy.
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